General Information of Drug (ID: DM7E1W0)

Drug Name
CC-95251 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7E1W0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FSI-189 DMPENAL Non-hodgkin lymphoma 2B33.5 Phase 1 [2]
BI 765063 DMZMAOW Solid tumour/cancer 2A00-2F9Z Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inhibitory receptor SHPS-1 (SIRPA) TTBRJS9 SHPS1_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health.
2 T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391.
3 Clinical pipeline report, company report or official report of OSE Immunotherapeutics.